Stay updated with breaking news from Atriva. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut. ....
DGAP-News: Atriva Therapeutics GmbH / Key word(s): Conference Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022 20.12.2021 / 10:00 The ....
DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding 21.04.2021 / 16:03 Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding German Federal Ministry of Education and Research (BMBF) awards Atriva up to €11.4 million for the clinical development of a drug to treat COVID-19 Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment Targeting RNA viruses and acting in the host cell, drug candidate can retain full activity even with SARS-CoV-2 variants Therapeutic aims to inhibit replication of virus and to prevent overshooting immune response ....